Regeneron Pharmaceuticals Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $1.98B | $18.77B | $2.89B |
| FY2022 | $1.98B | $22.66B | $3.11B |
| FY2023 | $1.98B | $25.97B | $2.73B |
| FY2024 | $1.98B | $29.35B | $2.49B |
| FY2025 | $1.99B | $31.26B | $3.12B |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | $1.98B | $18.77B | $2.89B |
| FY2022 | $1.98B | $22.66B | $3.11B |
| FY2023 | $1.98B | $25.97B | $2.73B |
| FY2024 | $1.98B | $29.35B | $2.49B |
| FY2025 | $1.99B | $31.26B | $3.12B |